Combination of Lovaza 4g and Rosuvastatin 10mg is Safe
Yes, 4 grams of Lovaza (omega-3-acid ethyl esters) can be safely combined with rosuvastatin 10 mg in a patient with triglycerides of 368 mg/dL. This combination is both appropriate and well-supported by evidence, with no clinically significant drug-drug interactions.
No Pharmacokinetic Interaction
The combination has been specifically studied and demonstrates no effect on statin pharmacokinetics. A dedicated drug interaction study showed that administration of 4g omega-3-acid ethyl esters with rosuvastatin 40 mg daily for 14 days did not affect the area under the curve (AUC) or maximum plasma concentration (Cmax) of rosuvastatin under steady-state conditions 1. This confirms no pharmacokinetic interaction exists between these medications.
Clinical Efficacy of the Combination
For your patient with triglycerides of 368 mg/dL, this combination offers complementary lipid-lowering benefits:
Triglyceride reduction: The ROMANTIC trial demonstrated that adding omega-3 fatty acids 4g daily to rosuvastatin 20mg in patients with residual hypertriglyceridemia produced significantly greater triglyceride reduction (-26.3% vs -11.4%, P < 0.001) compared to rosuvastatin alone 2
Non-HDL cholesterol improvement: The same study showed superior non-HDL-C reduction (-10.7% vs -2.2%, P = 0.001) with combination therapy 2
No increase in adverse events: Safety profiles were comparable between combination and monotherapy groups 2
FDA-Approved Indication
Lovaza is FDA-approved as an adjunct to diet to reduce triglyceride levels in adults with severe (≥500 mg/dL) hypertriglyceridemia 3. While your patient's level of 368 mg/dL doesn't meet the "severe" threshold, the medication is commonly used for moderate hypertriglyceridemia in clinical practice, particularly when combined with statins.
Dosing Considerations
- Lovaza: 4 grams daily, taken either as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules twice daily) with meals 3
- Rosuvastatin: Continue 10 mg daily as prescribed
- Capsule administration: Advise the patient to swallow Lovaza capsules whole—do not break, crush, dissolve, or chew 3
Important Safety Monitoring
Atrial Fibrillation Risk
Monitor for atrial fibrillation, particularly in the first few months of therapy. Multiple trials have demonstrated increased AF risk with prescription omega-3 fatty acids at doses of 1.8-4g daily 4. The 2021 ACC Expert Consensus specifically notes this concern and recommends evaluating the net benefit in patients at high risk for AF 4. The Lovaza FDA label also warns about possible association with more frequent recurrences of symptomatic AF or flutter 3.
Bleeding Time
Omega-3 fatty acids may prolong bleeding time. If your patient is taking anticoagulants or antiplatelet agents, monitor periodically 3.
LDL-Cholesterol
Lovaza may increase LDL-C levels 3. Monitor LDL levels periodically, though studies suggest omega-3s may actually improve LDL particle size toward a less atherogenic profile 5.
Hepatic Function
In patients with hepatic impairment, monitor ALT and AST periodically 3.
Common Pitfalls to Avoid
Do not substitute over-the-counter fish oil supplements for prescription Lovaza: Non-prescription fish oil products are dietary supplements with variable content, inconsistent purity, and no FDA approval for treating elevated triglycerides 4. They have not demonstrated cardiovascular outcomes benefits and are not recommended for ASCVD risk reduction 4.
Ensure dietary modification: Both medications should be used as adjuncts to appropriate lipid-lowering diet 3
Fish/shellfish allergy: Use Lovaza with caution if the patient has known hypersensitivity to fish or shellfish 3
No Contraindication with Rosuvastatin
The 2016 AHA Scientific Statement on statin drug-drug interactions does not list omega-3 fatty acids as having clinically significant interactions with any statins 6. The guideline focuses on agents that affect CYP450 enzymes and P-glycoprotein transporters—mechanisms not relevant to omega-3 fatty acids.
Bottom line: Proceed with the combination of Lovaza 4g daily and rosuvastatin 10mg daily, monitor for atrial fibrillation especially in the first few months, and recheck lipid panel in 8-12 weeks to assess response.